Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition).
Purpose: Radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) has become a challenge in clinical practice, particularly in China with a high incidence and undesirable survival outcome. Since the publication of first China consensus on the diagnosis and treatment of RAIR-DTC in 2019...
| Published in: | European Journal of Nuclear Medicine & Molecular Imaging Vol. 52; no. 10; pp. 3859 - 3877 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Published: |
Springer Nature
Aug2025
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=187119031&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 187119031 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 16197070 NPC jtl: European Journal of Nuclear Medicine & Molecular Imaging issn: 16197070 maglogo: N pubinfo: dt: Aug2025 vid: 52 iid: 10 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 187119031 183966397 10.1007/s00259-025-07222-1 187119031 ppf: 3859 ppct: 18 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition). aug: au: Lin, Yan-Song Wang, Ren-Fei Huang, Rui Wen, Qiang Cao, Wei Chen, Li-Bo Guo, Ye Hou, Xiao-Rong Li, Li Li, Xiao-Yi Lin, Cheng-He Liu, Zhi-Yan Wang, Hao Wang, Xu-Fu Wang, Zhuo-Ying Wu, Xiao-Hong Xu, Shu-Hang Yang, Ai-Min Zhang, Bo Zhang, Yue-Lun affil: https://ror.org/02drdmm93 Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China sug: ab: Purpose: Radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) has become a challenge in clinical practice, particularly in China with a high incidence and undesirable survival outcome. Since the publication of first China consensus on the diagnosis and treatment of RAIR-DTC in 2019, significant and rapid advances have occurred in the field both in China and internationally. This guideline aims to inform Chinese clinicians, researchers, patients, and health policy makers on the latest evidence and recommendations, to further standardize the clinical diagnosis and treatment of RAIR-DTC. Methods: The structured clinical questions addressed in this guideline were derived from clinical diagnostic and treatment processes, with references to study, prior guidelines, expert consensus, and systematic reviews, etc. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was used for quantitative and qualitative evaluation of the evidence. The editorial process was completely independent of the guideline development group. Results: The guideline addressed 26 clinical questions and formed 35 recommendations. In this guideline, the definition criteria for RAIR-DTC was optimized, prediction and identification was based on evidence including molecular testing, dynamic biochemical changes, and multimodal imaging. Comprehensive pre-treatment clinical evaluation was emphasized and tailored for individualized decision-making. The combination of systematic therapy and surgery, and the redifferentiation followed by RAI therapy were also reviewed and updated. Molecular imaging plays a unique role in the pre-assessing and therapeutic response evaluation for RAIR-DTC. Conclusions: We have updated and developed evidence-based recommendations with the aim of providing scientific, rigorous, and comprehensive guidance for the clinical diagnosis and treatment of RAIR-DTC patients in China. We hope to share our guideline with colleagues out of China, with the expectation of further comments and suggestions. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|